Citations

Clear

959 citation(s) found for "Service, F J".

Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy
Munblit, Daniel , Semple, Malcolm G. , Genuneit, Jon , Ashkenazi‐Hoffnung, Liat , Poland, Gregory A, Bush, Andrew, Boaventura, Viviane, Ulloa‐Gutiérrez, Rolando , Buonsenso, Danilo , Semple, Malcolm G , Genuneit, Jon , Ashkenazi-Hoffnung, Liat , Sultan, Faisal , Putri, Nina Dwi , Apfelbacher, C J , Ulloa-Gutierrez, Rolando , Watson, Hugh R , Oliveira, Carlos R , Reyes, Luis Felipe , Olliaro, Piero , Greenhawt, Matthew , Wilder‐Smith, Annelies , Warner, John O. , Chang, Aileen Y. , Poland, Gregory A. , Boaventura, Viviane Sampaio , Apfelbacher, Christian , Oliveira, Carlos R.

Mayo Clinic

Clinical Infectious Diseases | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag403 | PMID 42554662 Get It

Abstract Unvetted scientific claims about vaccines can spread rapidly and undermine decades of progress in immunization and public trust. A recent non-peer-reviewed analysis, promoted at political hearings, in the documentary “An Inconvenient Study,” and on social media, has been used to suggest that vaccinated children experience higher rates of chronic illness than unvaccinated peers. Despite standard regression models, critical flaws - uncontrolled confounding, exposure misclassification, unequal follow-up, and outcome multiplicity, invalidate causal inference. An independent group of international experts critically appraises this analysis and contrast its claims with the consistent evidence confirming vaccine safety and effectiveness. We also show how poorly designed studies can distort public discourse, amplify misinformation, and fuel vaccine hesitancy. We outline actions to strengthen research integrity, such as transparent data sharing, labeling of non-peer-reviewed content, and evidence-based communication. Safeguarding public health demands that vaccine evidence be methodologically sound, reviewed, and interpreted by qualified experts.
Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: ‘Auckland Classification’ v1.0
Varghese, Chris , Dachs, Nicky , Schamberg, Gabriel , Abell, Thomas, Al‐Haddad, Mohammad, Angeli, Timothy R. , Ayubi, Homira , Bashashati, Mohammad , Bulat, Robert, Calder, Stefan, Cederwall, Christopher Brian, Chang, Bianca W. , Cheng, Leo K. , Clarke, John, Daker, Charlotte , Du, Peng, Erickson, Jon, Eriksson, Sven, Fikree, Asma , Foong, Daphne , Fox, Mark, Goenka, Mahesh, Haidry, R, Holtman, Gerald, Hobson, Anthony , Koloski, Natasha, Kuo, Braden, Law, Mikaela, Levinthal, D., Liu, Joy , Mathur, Prateek , Moshiree, Baharak, Ngo, Catherine, Nguyen, Linda, Oblizajek, Nicholas R. , Parkman, Henry P., Podboy, Alexander, Rezaie, Ali, Simmonds, Sam , Sivakumar, Jonathan , Sirimongkolkasem, Jarongkorn , Sonu, Irene, Stocker, Abigail, Sujka, Joseph, Tack, Jan, Weinstein, Douglas, Windsor, John, Zarate‐Lopez, Natalia, Andrews, Christopher N., O'Grady, Greg, Clarke, John O. , Angeli-Gordon, Timothy R , Chang, Bianca , Cheng, Leo K , Daker, Charlotte , Ghoshal, Uday C , Hasler, W L , Ho, Vincent , Keszthelyi, Daniel , Khalsa, Sahib S , Liu, Joy J , Neshatian, Leila , Oblizajek, Nicholas R , Pandanaboyana, Sanjay , Sharma, Amol , Wang, Xiao Jing , Xu, William , Varghese, Chris , Clarke, J , Schamberg, Gabriel , Al‐Haddad, Mohammad , Ayazi, Shahin , Bulat, Robert, Calder, Stefan , Cederwall, Chris, Du, Peng , Erickson, Jonathan C. , Ghoshal, Uday C. , Hasler, William L. , Hayee, Bu , Ho, Vincent , Huang, I‐Hsuan , Khalsa, Sahib S. , Kuo, Braden , Kunkel, David C. , Law, Mikaela , Levinthal, David J. , Moshiree, Baharak , Neshatian, Leila , Parkman, Henry P. , Podboy, Alexander , Rezaie, Ali , Sonu, Irene S. , Stocker, Abigail, Sujka, Joseph , Tack, Jan , Verdonk, Charles , Wang, Xiao Jing , Wongjarupong, Nicha , Xu, William , Andrews, Christopher N. , Gharibans, Armen A.

Mayo Clinic

Neurogastroenterology & Motility | July 1, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70377 | PMID 42381563 Get It

ABSTRACT Introduction Chronic gastroduodenal disorders remain challenging to manage, and new diagnostic approaches are needed to better delineate underlying causes and guide therapeutic decisions. Body Surface Gastric Mapping (BSGM) technologies combine high‐resolution gastric myoelectrical activity measurements with symptom and psychological profiling to provide mechanistic insights into gastric motor and sensory dysfunction. An International Working Group convened to derive the first consensus classification of BSGM phenotypes (the “Auckland Classification”). Methods A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement. Results Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut‐brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism‐based treatment guidelines. Ten out of the eleven statements had > 80% agreement. Conclusions The Auckland Classification, derived by international consensus, presents a structured framework for BSGM‐defined patient phenotypes. Evidence and mechanism‐based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.
Reading Performance and Eye Movement Patterns in Glaucoma
Ikeda, Mariana Chiba , Messias, André M V, Hamada, Koiti Uchida, Bando, André Hiroshi, Nakamura, Vinícius P L, Gracitelli, Carolina P B, Chiba Ikeda, Mariana , Messias, André Marcio Vieira , Teixeira, Sérgio Henrique , Nakamura, Vinícius Pereira Leite, Prata, Tiago S. , Tatham, Andrew J. , Paranhos, Augusto , Gracitelli, Carolina P B

Mayo Clinic

Journal of Glaucoma | June 23, 2026 | Volume: 35 | Issue: 7 | Pages: 501-507

10.1097/ijg.0000000000002727 | PMID 42335967 Get It

Précis: Glaucoma patients of similar age and educational level, compared with healthy individuals, exhibit a greater number of saccades and fixations during eye-tracking-aloud reading, resulting in reduced reading speed. Purpose: To evaluate reading performance in patients with glaucoma compared with controls using an eye tracker and to explore the potential confounding effects of patients’ contrast sensitivity and cognition. Materials and Methods: A cross-sectional study was conducted with 111 participants (57 with glaucoma and 54 controls) with a best-corrected visual acuity of ≥0.5 logMAR. Cognition was assessed using the Montreal Cognitive Assessment, and contrast sensitivity was measured with the Freiburg Visual Acuity and Contrast Test. A reading performance evaluation was conducted using the Minnesota Low Vision Reading Test displayed on slides on a computer screen. Reading speed was calculated in words per minute, and an eye tracker was used to analyze saccade and fixation patterns during the reading task. Results: Mean age was 61.8 (±11.6) and 66.5 (±13.7) in the glaucoma and control groups, respectively ( P =0.05). Best-corrected visual acuity was 0.18 (±0.16) and 0.04 (±0.10) logMAR in the glaucoma and control groups, respectively ( P <0.001). Montreal Cognitive Assessment score was 21.8 (±3.5) in the glaucoma and 21.4 (±4.0) in the control group ( P =0.566). A total of 26% of the glaucoma group and 33% of the control group had at least a primary education. Controls read faster and showed fewer saccades and fixations than patients with glaucoma ( P <0.05) across all 5 slides. Conclusions: Patients with glaucoma exhibit poorer reading performance, as evidenced by eye-tracking data, compared with controls of similar age, cognitive function, and educational level.
Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Maclachlan, Kylee , Papadimitriou, Marios , Blaney, Patrick , Baughn, Linda B. , Shekarkhand, Tala , Poos, Alexandra M. , Ziccheddu, Bachisio , Tang, Hongwei , Yan, Huihuang , Diamond, Benjamin , Zhang, Yanming , Cimera, Robert , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Tan, Carlyn , Brown, Elizabeth , Winterkorn, Lara , Steinsnyder, Zoe , Vaksman, Zalman , Korde, Neha , Weinhold, Niels , Maclachlan, Kylee , Tang, Hongwei , Dogan, Ahmet , Gagler, Dylan , Boyle, Eileen M , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Shah, Urvi A , Tan, Carlyn R , Brown, Elizabeth E , Winterkorn, Lara , Chu, Timothy , Steinsnyder, Zoe , Vaksman, Zalman , Davies, Faith E , Korde, Neha , Landgren, C Ola , Raab, Marc S , Lesokhin, Alexander M , Robine, Nicolas , Weinhold, Niels , Usmani, Saad , Maura, Francesco , Morgan, Gareth J , Baughn, Linda B , Diamond, Benjamin T , Blaney, Patrick , Poos, Alexandra M. , Doǧan, Ahmet , Boyle, Eileen M. , Shah, Urvi A. , Davies, Faith E. , Landgren, Ola , Raab, Marc S. , Lesokhin, Alexander M. , Usmani, Saad Z. , Maura, Francesco , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF17

10.1158/2643-3230.bcd-25-0259 | PMID 42284538 Get It

Abstract Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma. To comprehensively investigate somatic drivers in relation to inherited genetics in multiple myeloma, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing multiple myeloma between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiologic data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop multiple myeloma at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes. Significance: Multiple myeloma is reported to occur at higher rates in individuals who self-identify as non-Hispanic Black. In this large dataset, genomic drivers occur at the same rate among ancestry groups, except for APOBEC mutagenesis. With equivalent therapy, clinical outcomes did not differ for patients grouped by genetic ancestry similarity.
Pediatric epilepsy surgery: Global survey of invasive explorations
Ramantani, Georgia , Feucht, Martha , Cserpán, Dorottya , Aparicio, Javier , Arzimanoglou, Alexis , Bartoloméi, Fabrice , Bingaman, William , Braun, Kees P. J. , Burman, Richard J. , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cross, J. Helen , Cukiert, Cristine Mella , Curry, Daniel J. , Dimova, Petia , Eltze, Christin , Hallböök, T , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt, Patil, Sandeep Bhagwan , Pérez‐Jiménez, María Ángeles, Pérez‐Poveda, Juan Carlos , Pieper, Tom , Rona, Sabine, Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta‐Arsene, Oana , Tripathi, Manjari , Moosa, Ahsan N. , Weiner, Howard , Cai, Lixin , Sorbets, Sarah Ferrand , Group, ILAE Pediatric Epilepsy Surgery Taskforce and Study, Barba, Carmen , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cross, Helen J , Cukiert, Arthur , Curry, Daniel J , De Palma, Luca , Dimova, Petia , Eltze, Christin , Englot, Dario J , Nico Enslin, Johannes M , Fallah, Aria , Francione, Stefano , Gill, Deepak , Harvey, A Simon , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt , Patil, Sandeep Bhagwan , Pérez-Poveda, Juan Carlos , San Antonio-Arce, Victoria , Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta Arsene, Oana , Tassi, Laura , Tisdall, Martin M , Tripathi, Manjari , Valappil, Ahsan Moosa Naduvil , Wirrell, Elaine C , Cai, Li-Xin , Ferrand Sorbets, Sarah , Wilmshurst, Jo M , Ramantani, Georgia , Feucht, Martha , Burman, Richard J , Englot, Dario J. , Enslin, Nico , Fallah, Aria , Gill, Deepak , Pérez-Jiménez, María Ángeles, Tisdall, Martin , Wirrell, Elaine , Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Barba, Carmen

Mayo Clinic

Epilepsia | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70325 | PMID 42274288 Get It

Abstract Objective Invasive presurgical evaluation plays a key role in pediatric epilepsy surgery, particularly in magnetic resonance imaging (MRI)‐negative cases, by guiding resective, disconnective, or ablative procedures. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Taskforce study provides an updated global overview of current invasive evaluation practices. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) in 29 countries across six continents. Included were children and adolescents who underwent presurgical evaluation and epilepsy surgery in 2023. The study was designed to enable comparison with the similar ILAE survey conducted in 2004. Results A total of 2427 patients were included. Invasive evaluations were performed in 21.1% of cases, most frequently in North America (33.7%, higher than Europe: 18.0%, p = .003). Among invasive cases, 32.3% had no detectable MRI abnormalities. The main indication for invasive evaluation was seizure onset localization (88.1%), followed by motor or sensory mapping (17.2%) and language mapping (14.2%). Stereoelectroencephalography (SEEG) was the predominant technique (19.8% overall, 93.6% of invasive cases), more common in North America (30.0%, p = .021) and less common in South America (7.4%, p < .001). Subdural electrodes were used in only 3.2% of invasive cases, and combined depth and subdural approaches in 3.2%. SEEG‐guided radiofrequency thermocoagulation (RF‐TC) was performed in 40.9% of SEEG cases, most commonly in Asia (63.8%). In 16.2% of invasive evaluations, patients did not proceed to resection, disconnection, or ablation, with the highest rate in Europe (28.5%). Significance This global survey provides the first broad overview of invasive evaluation practices in pediatric epilepsy surgery across participating centers worldwide. It highlights the widespread adoption of SEEG, declining use of subdural electrodes, and increasing application of SEEG‐guided RF‐TC. The high proportion of MRI‐negative cases and the considerable proportion of patients not proceeding to resection, disconnection, or ablation underscore the complexity of contemporary surgical candidates and the need for further refinement of selection strategies.
Zorevunersen Demonstrates Potential as a Disease-modifying Therapy in Patients with Dravet Syndrome Through Durable Seizure Reduction and Improvements in Cognition, Behavior, and Quality of Life Through 36 Months of Treatment in Open-label Extension Studie
Laux, Linda, Cross, J Helen, Perry, M Scott, Sullivan, Joseph, Desurkar, Archana , Roberts, Colin M., Wheless, James W., Ventola, Pam, Werneburg, Brian, Lynch, Jessie, Wang, Fei, Parkerson, Kimberly A. , Ticho, Barry, Cross, J. Helen , Cross, Helen J , Laux, Linda , Knupp, Kelly G. , Brunklaus, Andreas , Perry, Michael Scott , Schreiber, John R. , Roberts, Colin, Wheless, James W. , Wirrell, Elaine , Ticho, Barry

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217057 Get It

Patterns of Drop Seizure Outcome after Corpus Callosotomy in Children (P11-11.010)
Yucht, Alexander, Miller, Kai, Fine, Anthony, Nickels, Katherine, Starnes, Donnie, Wirrell, Elaine, Youssef, Paul, Wong-Kisiel, Lily, Tsai, Ming‐Chen , Fine, Anthony L. , Nickels, Katherine , Wirrell, Elaine

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215599 Get It

Pediatric epilepsy surgery: Global survey of referral and presurgical evaluation practices
Ramantani, Georgia , Cross, J. Helen , Cserpán, Dorottya , Ahemad, Emtnan , Aparicio, Javier , Arzimanoglou, Alexis , Barba, Carmen , Bingaman, William , Braun, Kees , Burman, R J, Cai, Lixin , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cukiert, Cristine Mella , Dal, Sameer , Englot, Dario, Enright, Noelle , Sorbets, Sarah Ferrand , Mahecha, Laura Guio, Hallböök, T , Harvey, A. Simon, Holthausen, H, Jiang, Y , Kannan, Lakshminarayanan , Lallas, Matt, Valappil, Ahsan Moosa Naduvil , Patil, Sandeep Bhagwan , Pieper, Tom , Tripathi, Manjari , Vendégh, Lejla, Weiner, Howard , Wilmshurst, Jo, Smith, MK, Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Wilmshurst, Jo M. , Burman, Richard J. , Shetty, Jay , Burman, Richard J , Butler, James , Cai, Li-Xin , Cao, Dezhi , Caraballo, Roberto H , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cukiert, Arthur , Dal, Sameer , Englot, Dario J , Enright, Noelle , Fallah, Aria , Ferrand Sorbets, Sarah , Feucht, Martha , Gill, Deepak , Hadjinicolaou, Aristides , Harvey, A Simon , Holthausen, Hans , Jiang, Yuwu , Kannan, Lakshminarayanan , Katlowitz, Kalman A , Kotulska-Jóźwiak, Katarzyna , Kudr, Martin , Lallas, Matt , Patil, Sandeep Bhagwan , Specchio, Nicola , Tripathi, Manjari , Wilmshurst, Jo M , Smith, Mary Lou , Wirrell, Elaine C , Ramantani, Georgia , Cross, Helen J , Shetty, Jay , Barba, Carmen , Braun, Kees P. J. , Englot, Dario J. , Fallah, Aria , Feucht, Martha , Moosa, Ahsan N. , Specchio, Nicola , Wirrell, Elaine

Mayo Clinic

Epilepsia | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70312 | PMID 42227967 Get It

Abstract Objective Pediatric epilepsy surgery is well established, but contemporary global data on referral and presurgical evaluation practices are lacking. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Task Force study provides an updated overview of current trends and regional differences. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) across 29 countries and six continents, identified through ILAE networks, and included all children and adolescents treated in 2023 who underwent presurgical evaluation/epilepsy surgery. Results Group‐level data were available for 2427 patients. Mean age at surgery was 9.1 ± 4.9 years; mean epilepsy duration was 5.3. At surgery, 3.2% were <1 year old (highest in Oceania: 5.1%), and 6.1% were nonpharmacoresistant (highest in Europe: 15.0%). Prior neurosurgery was reported in 14.2% (highest in North America: 28.8%), including 8.0% resections (6.1% for epilepsy, 1.5% for tumors; highest in Oceania: 16.5%), 2.3% disconnections (1.3% corpus callosotomy; highest in South America: 4.7%), and 4.2% neuromodulation (3.7% vagal nerve stimulation, .2% responsive neurostimulation, one deep brain stimulation; highest in North America: 12.2%). Developmental and epileptic encephalopathies (DEEs) at surgery included Lennox–Gastaut syndrome (7.4%), infantile epileptic spasms syndrome (5.1%), and DEE with spike–wave activation in sleep (1.5%). Presurgical investigations included fluorodeoxyglucose positron emission tomography (52.6%; highest in Oceania: 79.7%), genetic testing (46.8%; highest in Asia: 54.3%), magnetic resonance imaging (MRI) postprocessing (32.4%; highest in South America: 53.0%), functional MRI (fMRI; 15.2%; highest in North America: 40.3%), magnetoencephalography (11.9%; highest in North America: 39.3%), single photon emission computed tomography (9.6%; highest in North America: 22.2%), high‐density electroencephalography (EEG; 1.9%; highest in Europe: 4.7%), source localization (1.6%; highest in Oceania: 7.6%), Wada test (1.2%; highest in North America: 3.5%), and EEG‐fMRI (.5%; highest in Europe: 1.1%). Significance Despite some early surgeries, including in infancy and before pharmacoresistance, mean epilepsy duration before surgery remains >5 years. Reoperations are common, with resection more frequent than neuromodulation. Genetic testing in nearly half of patients reflects its growing relevance, and the high rate of DEEs underscores the complexity of surgical candidates.
Darier disease—A review highlighting new insights from the Darier Disease International Task Force
Labbouz, Sofia , Xiong, Grace , Murrell, Dedee Frances, Mueller, Simon M. , Mohandesi, Nessa Aghazadeh, Aldhaheri, Ahmed Salem, Asayag, Nissim, Baselga, Eulalia, Nadler, Chen , Chu, Chia‐Yu , Edminister, John R. , Guenova, Emmanuella, Gönülal, Melis , Gostynski, Antoni, Gupta, Lalit Kumar, Mazereeuw‐Hautier, Juliette, Hoetzenecker, Wolfram , Itin, Peter, Jankowski, Marek , Medvecz, Márta, Moosbrugger‐Martinz, Verena , Paller, Amy S., Plázár, Dóra , Queiróz, Amadeu José Rodrigues , Riera‐Monroig, Josep , Rosa, Ralph, Schmuth, Matthias, Freire, Maella Severino , Shabat, Itzhak, Shapiro, Jonathan , Soto‐García, Diego , Stratigos, Alexander J., Tadini, Gianluca Abel, Takeichi, Takuya , Verma, Kaushal K. , Wikström, Jakob D. , Ziv, Michael , Dodiuk‐Gad, Roni Pircha, Xiong, Grace , Mueller, Simon M , Ezzedine, Khaled , Choate, Keith , Gostynski, Antoni , Gupta, Ankan , Hoetzenecker, Wolfram , Jankowski, Marek , Kubo, Akiharu , Lee, Haur Yueh , Lehman, Julia Scott, Mellerio, Jemima E , Queiróz, Amadeu José Rodrigues , Freire, Maella Severino , Shapiro, Jonathan , Soto-García, Diego , Takeichi, Takuya , Wikström, Jakob D , Zink, Alexander , Navarini, Alexander , Hovnanian, Alain , Murrell, D F , Aghazadeh, Nessa , Aldhaheri, Ahmed S., Guenova, Emmanuella , Gönülal, Melis , Mazereeuw‐Hautier, J. , Lehman, Julia S. , Lepekhova, Anfisa A. , Medvecz, Márta, Paller, Amy S. , Schmuth, Matthias , Simpson, Cory L. , Tadini, Gianluca , Wikström, Jakob D. , Dodiuk‐Gad, Roni P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70483 | PMID 42223188 Get It

Abstract Darier disease (DD) is a rare autosomal dominant genodermatosis. This comprehensive review, developed by the Darier Disease International Task Force (DDITF), consolidates current knowledge on the genetic basis, molecular pathophysiology, clinical presentation, diagnosis and management of DD, offering a global perspective that unites shared expertise. The disease arises from pathogenic variants in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum Ca 2+ ‐ATPase isoform 2 (SERCA2), leading to disrupted calcium homeostasis and impaired desmosomal integrity. Clinically, DD is classified based on lesion type (classic vs. non‐classic) and is often accompanied by significant extracutaneous manifestations. Management remains challenging and requires a multifaceted approach, including topical therapies, systemic retinoids and lifestyle modifications. Emerging treatments that target the underlying molecular mechanisms offer promise for improved outcomes. This review aims to provide an updated reference and practical guidance for clinicians involved in the care and study of DD.
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
Wechalekar, Ashutosh D., Dispenzieri, Angela, Sanchorawala, Vaishali, Kastritis, E K, Zepeda, Victor H. Jimenez-, Suzuki, Kenshi, Lentzsch, Suzanne , Huart, Antoine , Carpinteiro, Alexander , Swenson, Eugene , Khan, Zilehuma, Catini, Julia, Kulkarni, Hrishikesh, Meltzer, Brian Adam, Mercuri, Michele, Lake, Stephen, Liedtke, Michaela , Investigators, On Behalf of the Pittsburgh Post Cardiac Arrest Service, Wechalekar, Ashutosh D. , Dispenzieri, Angela , Sanchorawala, Vaishali , Bhutani, Divaya , Bianchi, Giada , Suzuki, Kenshi , Khan, Zilehuma, Kulkarni, Hrishikesh, Lake, Stephen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7501-7501

10.1200/jco.2026.44.16_suppl.7501 Get It

7501 Background: AL amyloidosis is a plasma cell dyscrasia (PCD) characterized by κ or λ Ig light chain amyloid fibrils that deposit in vital organs. Anselamimab is an investigational mAb designed to complement anti-PCD therapy through accelerated removal of amyloid fibrils. Cardiac Amyloid Reaching for Extended Survival (CARES) studies (NCT04512235 and NCT04504825) investigated the efficacy and safety of anselamimab compared with placebo, in addition to anti-PCD therapy. Methods: Alongside anti-PCD therapy with CyBorD (daratumumab was permitted) newly diagnosed patients with European modification of Mayo stage IIIa or IIIb AL amyloidosis were randomized 2:1 to receive anselamimab (1000 mg/m 2 ) or placebo (normal saline) IV every 7 days for 4 weeks followed by every 14 days for the remainder of the blinded study (18 months after the last participant enrolled). The primary endpoint was a hierarchical combination of time to all-cause mortality (ACM) and frequency of adjudicated cardiovascular hospitalizations (CVH) using the Finkelstein-Schoenfeld test and win-ratio in the combined study population. Subgroup analysis by involved κ or λ free light chain (iFLC) was prespecified. Results: 271 patients were randomized to receive anselamimab and 135 placebo. Baseline characteristics were similar between treatment arms. The median duration of treatment was 21.4 months and 21.1 in the anselamimab and placebo arms, respectively. Daratumumab was used in 79.3% and 83.7% of the anselamimab and placebo arms, respectively. Results of the primary efficacy analyses are shown in the table. Anselamimab-treated patients with κ iFLC had a 62% reduction in ACM (HR = 0.38; 95% CI, 0.17, 0.86; nominal P = 0.012) and a 71% reduction in risk for CVH (estimated CVH rate ratio = 0.29; 95% CI, 0.10, 0.87; nominal P = 0.028). Patients with λ iFLC had a 10% reduction in risk for CVH; none in ACM. Safety data were comparable between both treatment arms. In anselamimab-treated patients, safety findings were similar between κ subgroup and full population. Conclusions: Anselamimab, a κ light chain–directed anti-fibril monoclonal antibody used alongside standard of care chemotherapy, offers a first-in-class, new therapeutic option for patients with newly diagnosed κ AL amyloidosis. Clinical trial information: NCT04512235 and NCT04504825 . Summary of primary efficacy endpoints. Endpoint Overall κ Isotype λ Isotype Anselamimab (N=271) Placebo (N=135) P -value Anselamimab (N=48) Placebo (N=24) P -value Anselamimab (N=219) Placebo (N=109) P -value ACM and CVH win ratio (95% CI) 1.1 (0.8, 1.5) 0.332 2.06 (0.98, 4.31) 0.100 0.9 (0.6, 1.3) 0.848 ACM n (%) 90 (33.2) 52 (38.5) 15 (31.3) 14 (58.3) 73 (33.3) 37 (33.9) HR (95% CI) 0.8 (0.6, 1.1) 0.290 0.38 (0.2, 0.9) 0.012 1.0 (0.7, 1.5) 0.647 CVH Frequency/year (95% CI) 0.6 (0.4, 0.8) 0.9 (0.6, 1.4) 0.145 0.41 (0.2, 0.8) 1.4 (0.6, 3.4) 0.028 0.7 (0.4, 1.0) 0.8 (0.4, 1.3) 0.664 Incidence risk ratio (95% CI) 0.7 (0.4, 1.2) 0.29 (0.1, 0.9) 0.9 (0.5, 1.7)